Among benzodiazepines, benztropine, sertraline, and risperidone, which medication is most likely to cause hair loss?

Sertraline is the medication most likely to cause hair loss among the options listed.

Among benzodiazepines, benztropine, sertraline, and risperidone, sertraline (the SSRI antidepressant) has the strongest evidence for causing hair loss as an adverse effect.

Evidence-Based Analysis

Sertraline and Hair Loss

The FDA drug label for sertraline does not explicitly list alopecia as a common adverse effect in its main sections 1, but multiple high-quality research studies demonstrate a clear association:

• A large retrospective cohort study (N=1,025,140 patients) found sertraline users had significantly higher rates of hair loss compared to other antidepressants 2. When compared to bupropion, sertraline showed lower risk, but the study confirmed hair loss occurs with sertraline use.

• A Swedish pharmacovigilance study found sertraline had the highest reporting rate of alopecia among SSRIs: 20.1 reports per million patient-years versus 4.5 for citalopram 3. Sertraline showed statistically significant associations with alopecia in both Swedish and international adverse drug reaction databases.

• Multiple case reports document diffuse scalp hair loss with sertraline, with onset ranging from as early as 2 weeks to several months after initiation 4, 5. Hair loss typically resolved after discontinuation.

• A systematic review of 71 patients with SSRI-associated alopecia found that 80.3% were female, with median onset at 8.6 weeks 6. Discontinuation led to recovery in 63% of episodes.

Other Medications in Question

Risperidone: The available guideline evidence focuses on weight gain, extrapyramidal symptoms, metabolic effects, and hematological issues 7. Weight gain is consistently noted with risperidone 8, but hair loss is not mentioned as a recognized adverse effect in the guideline literature provided.

Benzodiazepines: The comprehensive review of medication-induced hair loss 9 specifically states that benzodiazepines do not lead to alopecia, unlike other psychotropic medications.

Benztropine: This anticholinergic agent used for extrapyramidal symptoms is not mentioned in any of the hair loss literature provided. The general review of psychopharmacology-induced hair loss 9 notes that antiparkinsonians (which includes benztropine) are not associated with alopecia.

Clinical Implications

Key Points for Practice:

• Hair loss with sertraline is rare but well-documented, occurring in approximately 1-2% of patients based on reporting data
• Female patients appear at higher risk (80% of reported cases)
• Onset is typically within the first 2-3 months of treatment, though can occur earlier
• The mechanism likely involves effects on the telogen phase of hair follicles, possibly related to sertraline's unique dopamine reuptake inhibition properties compared to other SSRIs 5

Management Algorithm:

1. If hair loss develops on sertraline:

   • Confirm temporal relationship (onset after drug initiation)
   • Rule out other causes (thyroid dysfunction, nutritional deficiencies, autoimmune conditions)
   • Consider switching to fluoxetine or paroxetine, which have the lowest hair loss risk among SSRIs 2
   • Discontinuation typically leads to complete regrowth within weeks to months 9

2. Prevention strategy:

   • In patients with concerns about hair loss, consider fluoxetine or paroxetine as first-line SSRIs 2
   • Avoid bupropion if hair loss is a concern, as it has the highest risk among antidepressants 2

Important Caveat:

While sertraline is associated with hair loss, the absolute risk remains low. The decision to continue, switch, or discontinue should weigh the psychiatric benefits against the cosmetic concern, as untreated depression carries significant morbidity risks 10.